Lipoprotein(a) and Benefit of PCSK9 Inhibition in Patients With Nominally Controlled LDL Cholesterol

Digital

Autores:
Schwartz, Gregory G.
Szarek, Michael
Bittner, Vera A.
Diaz, Rafael
Goodman, Shaun G.
Jukema, J. Wouter
Landmesser, Ulf
López-Jaramillo, Patricio
Manvelian, Garen
Pordy, Robert
Scemama, Michel
Sinnaeve, Peter R.
White, Harvey D.
Steg, Gabriel
ODYSSEY Outcomes Committees and Investigators
Tipo de recurso:
Article of journal
Fecha de publicación:
2021
Institución:
Universidad de Santander
Repositorio:
Repositorio Universidad de Santander
Idioma:
eng
OAI Identifier:
oai:repositorio.udes.edu.co:001/6065
Acceso en línea:
https://doi.org/10.1016/j.jacc.2021.04.102
https://repositorio.udes.edu.co/handle/001/6065
Palabra clave:
Acute coronary syndrome
Lipoprotein(a)
Low-density lipoprotein cholesterol
PCSK9 inhibitor
Rights
openAccess
License
Atribución-NoComercial 4.0 Internacional (CC BY-NC 4.0)
id RUDES2_138e63eb064dc56cbe635e56107329ef
oai_identifier_str oai:repositorio.udes.edu.co:001/6065
network_acronym_str RUDES2
network_name_str Repositorio Universidad de Santander
repository_id_str
dc.title.spa.fl_str_mv Lipoprotein(a) and Benefit of PCSK9 Inhibition in Patients With Nominally Controlled LDL Cholesterol
title Lipoprotein(a) and Benefit of PCSK9 Inhibition in Patients With Nominally Controlled LDL Cholesterol
spellingShingle Lipoprotein(a) and Benefit of PCSK9 Inhibition in Patients With Nominally Controlled LDL Cholesterol
Acute coronary syndrome
Lipoprotein(a)
Low-density lipoprotein cholesterol
PCSK9 inhibitor
title_short Lipoprotein(a) and Benefit of PCSK9 Inhibition in Patients With Nominally Controlled LDL Cholesterol
title_full Lipoprotein(a) and Benefit of PCSK9 Inhibition in Patients With Nominally Controlled LDL Cholesterol
title_fullStr Lipoprotein(a) and Benefit of PCSK9 Inhibition in Patients With Nominally Controlled LDL Cholesterol
title_full_unstemmed Lipoprotein(a) and Benefit of PCSK9 Inhibition in Patients With Nominally Controlled LDL Cholesterol
title_sort Lipoprotein(a) and Benefit of PCSK9 Inhibition in Patients With Nominally Controlled LDL Cholesterol
dc.creator.fl_str_mv Schwartz, Gregory G.
Szarek, Michael
Bittner, Vera A.
Diaz, Rafael
Goodman, Shaun G.
Jukema, J. Wouter
Landmesser, Ulf
López-Jaramillo, Patricio
Manvelian, Garen
Pordy, Robert
Scemama, Michel
Sinnaeve, Peter R.
White, Harvey D.
Steg, Gabriel
ODYSSEY Outcomes Committees and Investigators
dc.contributor.author.none.fl_str_mv Schwartz, Gregory G.
Szarek, Michael
Bittner, Vera A.
Diaz, Rafael
Goodman, Shaun G.
Jukema, J. Wouter
Landmesser, Ulf
López-Jaramillo, Patricio
Manvelian, Garen
Pordy, Robert
Scemama, Michel
Sinnaeve, Peter R.
White, Harvey D.
Steg, Gabriel
ODYSSEY Outcomes Committees and Investigators
dc.contributor.researchgroup.spa.fl_str_mv Masira
dc.subject.proposal.eng.fl_str_mv Acute coronary syndrome
Lipoprotein(a)
Low-density lipoprotein cholesterol
PCSK9 inhibitor
topic Acute coronary syndrome
Lipoprotein(a)
Low-density lipoprotein cholesterol
PCSK9 inhibitor
description Digital
publishDate 2021
dc.date.issued.none.fl_str_mv 2021-08-03
dc.date.accessioned.none.fl_str_mv 2022-02-21T14:04:52Z
dc.date.available.none.fl_str_mv 2022-02-21T14:04:52Z
dc.type.spa.fl_str_mv Artículo de revista
dc.type.coar.fl_str_mv http://purl.org/coar/resource_type/c_2df8fbb1
dc.type.coarversion.fl_str_mv http://purl.org/coar/version/c_970fb48d4fbd8a85
dc.type.coar.spa.fl_str_mv http://purl.org/coar/resource_type/c_6501
dc.type.content.spa.fl_str_mv Text
dc.type.driver.spa.fl_str_mv info:eu-repo/semantics/article
dc.type.redcol.spa.fl_str_mv http://purl.org/redcol/resource_type/ART
dc.type.version.spa.fl_str_mv info:eu-repo/semantics/publishedVersion
format http://purl.org/coar/resource_type/c_6501
status_str publishedVersion
dc.identifier.ark.none.fl_str_mv https://doi.org/10.1016/j.jacc.2021.04.102
dc.identifier.uri.none.fl_str_mv https://repositorio.udes.edu.co/handle/001/6065
url https://doi.org/10.1016/j.jacc.2021.04.102
https://repositorio.udes.edu.co/handle/001/6065
dc.language.iso.spa.fl_str_mv eng
language eng
dc.relation.citationendpage.spa.fl_str_mv 433
dc.relation.citationissue.spa.fl_str_mv 5
dc.relation.citationstartpage.spa.fl_str_mv 421
dc.relation.citationvolume.spa.fl_str_mv 78
dc.relation.indexed.spa.fl_str_mv Scopus
dc.relation.ispartofjournal.spa.fl_str_mv Journal of the American College of Cardiology
dc.rights.coar.fl_str_mv http://purl.org/coar/access_right/c_abf2
dc.rights.accessrights.spa.fl_str_mv info:eu-repo/semantics/openAccess
dc.rights.creativecommons.spa.fl_str_mv Atribución-NoComercial 4.0 Internacional (CC BY-NC 4.0)
dc.rights.uri.spa.fl_str_mv https://creativecommons.org/licenses/by-nc/4.0/
eu_rights_str_mv openAccess
rights_invalid_str_mv Atribución-NoComercial 4.0 Internacional (CC BY-NC 4.0)
https://creativecommons.org/licenses/by-nc/4.0/
http://purl.org/coar/access_right/c_abf2
dc.format.extent.spa.fl_str_mv 13 p
dc.format.mimetype.spa.fl_str_mv application/pdf
dc.publisher.spa.fl_str_mv Elsevier
dc.publisher.place.spa.fl_str_mv USA
dc.source.spa.fl_str_mv https://www.sciencedirect.com/science/article/pii/S0735109721052475?via%3Dihub
institution Universidad de Santander
bitstream.url.fl_str_mv https://repositorio.udes.edu.co/bitstreams/3d225395-f4a0-4b4f-912e-d8922e034266/download
https://repositorio.udes.edu.co/bitstreams/fb7d32b6-87d4-4089-9aac-972d51b3d30a/download
https://repositorio.udes.edu.co/bitstreams/eb275252-0c94-4774-9305-edd649ce77b7/download
https://repositorio.udes.edu.co/bitstreams/f9af28d1-7ef9-49b0-a38e-de17310ae33f/download
bitstream.checksum.fl_str_mv 019378d936c8be8c381b45b6f7257deb
38d94cf55aa1bf2dac1a736ac45c881c
5dbe86c1111d64f45ba435df98fdc825
49455d060d06b2b29d1bd2e0b2531f82
bitstream.checksumAlgorithm.fl_str_mv MD5
MD5
MD5
MD5
repository.name.fl_str_mv Repositorio Universidad de Santander
repository.mail.fl_str_mv soporte@metabiblioteca.com
_version_ 1814159020326387712
spelling Schwartz, Gregory G.0b9e6dfc-0a1d-4287-aee3-7713fce86ece-1Szarek, Michaele170e054-026f-4b96-a3f9-bf538a71553f-1Bittner, Vera A.ab899d35-5158-4520-b79d-4e866540846e-1Diaz, Rafaelf2be4a74-501a-4e63-8bbd-965cbcf8c57b-1Goodman, Shaun G.7f7d25ba-48f2-4592-8b03-25be06199175-1Jukema, J. Woutere6ea1e4d-1059-465c-b34b-854ca0141a3e-1Landmesser, Ulfe2fd9c4a-a4e2-4cfa-82fe-82a9528084c3-1López-Jaramillo, Patriciof72eca20-6f41-45fe-a875-83c14605cb60-1Manvelian, Garen4313214f-cf48-4faa-a446-3961d8c5de48-1Pordy, Robertadb5a1bc-eeb7-4d31-bab1-bd073aa4d3e7-1Scemama, Michel6c3278cc-a589-4cc5-a2b1-d9ab678b83c4-1Sinnaeve, Peter R.f438e55b-0c51-485e-a6d4-9cbd6d9a6b03-1White, Harvey D.88cf0d68-0edb-4f0b-9457-53b047230cd0-1Steg, Gabriel5e15ab0e-e531-446a-8adf-a24611c97076-1ODYSSEY Outcomes Committees and Investigators18d1e891-7825-4987-8cab-b78c84a15489-1Masira2022-02-21T14:04:52Z2022-02-21T14:04:52Z2021-08-03DigitalBackground Guidelines recommend nonstatin lipid-lowering agents in patients at very high risk for major adverse cardiovascular events (MACE) if low-density lipoprotein cholesterol (LDL-C) remains ≥70 mg/dL on maximum tolerated statin treatment. It is uncertain if this approach benefits patients with LDL-C near 70 mg/dL. Lipoprotein(a) levels may influence residual risk. Objectives In a post hoc analysis of the ODYSSEY Outcomes (Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab) trial, the authors evaluated the benefit of adding the proprotein subtilisin/kexin type 9 inhibitor alirocumab to optimized statin treatment in patients with LDL-C levels near 70 mg/dL. Effects were evaluated according to concurrent lipoprotein(a) levels. Methods ODYSSEY Outcomes compared alirocumab with placebo in 18,924 patients with recent acute coronary syndromes receiving optimized statin treatment. In 4,351 patients (23.0%), screening or randomization LDL-C was <70 mg/dL (median 69.4 mg/dL; interquartile range: 64.3-74.0 mg/dL); in 14,573 patients (77.0%), both determinations were ≥70 mg/dL (median 94.0 mg/dL; interquartile range: 83.2-111.0 mg/dL). Results In the lower LDL-C subgroup, MACE rates were 4.2 and 3.1 per 100 patient-years among placebo-treated patients with baseline lipoprotein(a) greater than or less than or equal to the median (13.7 mg/dL). Corresponding adjusted treatment hazard ratios were 0.68 (95% confidence interval [CI]: 0.52-0.90) and 1.11 (95% CI: 0.83-1.49), with treatment-lipoprotein(a) interaction on MACE (Pinteraction = 0.017). In the higher LDL-C subgroup, MACE rates were 4.7 and 3.8 per 100 patient-years among placebo-treated patients with lipoprotein(a) >13.7 mg/dL or ≤13.7 mg/dL; corresponding adjusted treatment hazard ratios were 0.82 (95% CI: 0.72-0.92) and 0.89 (95% CI: 0.75-1.06), with Pinteraction = 0.43. Conclusions In patients with recent acute coronary syndromes and LDL-C near 70 mg/dL on optimized statin therapy, proprotein subtilisin/kexin type 9 inhibition provides incremental clinical benefit only when lipoprotein(a) concentration is at least mildly elevated. (ODYSSEY Outcomes: Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab; NCT01663402)Ciencias Médicas y de la Salud13 papplication/pdfhttps://doi.org/10.1016/j.jacc.2021.04.102https://repositorio.udes.edu.co/handle/001/6065engElsevierUSA433542178ScopusJournal of the American College of Cardiology© 2021 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation.info:eu-repo/semantics/openAccessAtribución-NoComercial 4.0 Internacional (CC BY-NC 4.0)https://creativecommons.org/licenses/by-nc/4.0/http://purl.org/coar/access_right/c_abf2https://www.sciencedirect.com/science/article/pii/S0735109721052475?via%3DihubAcute coronary syndromeLipoprotein(a)Low-density lipoprotein cholesterolPCSK9 inhibitorLipoprotein(a) and Benefit of PCSK9 Inhibition in Patients With Nominally Controlled LDL CholesterolArtículo de revistahttp://purl.org/coar/resource_type/c_6501http://purl.org/coar/resource_type/c_2df8fbb1Textinfo:eu-repo/semantics/articlehttp://purl.org/redcol/resource_type/ARTinfo:eu-repo/semantics/publishedVersionhttp://purl.org/coar/version/c_970fb48d4fbd8a85Todas las AudienciasPublicationORIGINALLipoprotein(a) and Benefit of PCSK9 Inhibition in Patients With Nominally Controlled LDL Cholesterol.pdfLipoprotein(a) and Benefit of PCSK9 Inhibition in Patients With Nominally Controlled LDL Cholesterol.pdfapplication/pdf253228https://repositorio.udes.edu.co/bitstreams/3d225395-f4a0-4b4f-912e-d8922e034266/download019378d936c8be8c381b45b6f7257debMD51LICENSElicense.txtlicense.txttext/plain; charset=utf-859https://repositorio.udes.edu.co/bitstreams/fb7d32b6-87d4-4089-9aac-972d51b3d30a/download38d94cf55aa1bf2dac1a736ac45c881cMD52TEXTLipoprotein(a) and Benefit of PCSK9 Inhibition in Patients With Nominally Controlled LDL Cholesterol.pdf.txtLipoprotein(a) and Benefit of PCSK9 Inhibition in Patients With Nominally Controlled LDL Cholesterol.pdf.txtExtracted texttext/plain5https://repositorio.udes.edu.co/bitstreams/eb275252-0c94-4774-9305-edd649ce77b7/download5dbe86c1111d64f45ba435df98fdc825MD53THUMBNAILLipoprotein(a) and Benefit of PCSK9 Inhibition in Patients With Nominally Controlled LDL Cholesterol.pdf.jpgLipoprotein(a) and Benefit of PCSK9 Inhibition in Patients With Nominally Controlled LDL Cholesterol.pdf.jpgGenerated Thumbnailimage/jpeg12240https://repositorio.udes.edu.co/bitstreams/f9af28d1-7ef9-49b0-a38e-de17310ae33f/download49455d060d06b2b29d1bd2e0b2531f82MD54001/6065oai:repositorio.udes.edu.co:001/60652023-10-09 16:53:24.719https://creativecommons.org/licenses/by-nc/4.0/© 2021 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation.https://repositorio.udes.edu.coRepositorio Universidad de Santandersoporte@metabiblioteca.comTGljZW5jaWEgZGUgUHVibGljYWNpw7NuIFVERVMKRGlyZWN0cmljZXMgZGUgVVNPIHkgQUNDRVNPCgo=